1) Molecular Target Therapy in Hematologic Malignancies
نویسندگان
چکیده
منابع مشابه
Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificit...
متن کاملTargeted therapy for hematologic malignancies.
BACKGROUND The introduction of monoclonal antibodies, either as native molecules or conjugated to radioisotopes or other toxins, has led to new therapeutic options for patients with hematologic malignancies. In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders. METHODS The aut...
متن کاملMolecular diagnostics of hematologic malignancies.
Hematologic malignancies, particularly lymphoma and leukemia, are a diverse group of diseases with a myriad of different presentations. Although the diagnosis of these diseases can be straightforward, there are many cases in which the diagnosis is difficult to establish with conventional methods. Molecular diagnostic testing to identify oncogenes and clonal lymphocyte populations can aid in res...
متن کاملInterleukin-2 in therapy of hematologic malignancies.
T HE ARTICLE BY Gisselbrecht et all in this issue of Blood describes the activity of single-agent interleukin-2 (IL-2) in a heterogeneous group of previously treated patients with malignant non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease, and cutaneous T-cell lymphoma (CTCL). The number of patients within each of the defined groups is relatively small, and the confidence intervals surrounding t...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nihon Naika Gakkai zasshi
سال: 2022
ISSN: ['1883-2083', '0021-5384']
DOI: https://doi.org/10.2169/naika.111.120a